bioXcelerate, a new and innovative health data science division of Optima Partners Limited, has revealed a new groundbreaking AI tool, which is set to accelerate the process for identifying and developing new drugs.
Evommune raises $115M for I&I pipeline and prepares for Phase 2 results
Another inflammation and immunology startup has attracted big bucks. On Thursday, Evommune announced a $115 million raise to back a pipeline anticipated to have multiple